Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017 (2017), Article ID 3826506, 9 pages
Research Article

Insights into the Roles of Midazolam in Cancer Therapy

1Department of Anesthesiology, The First Affiliated Hospital, China Medical University, Shenyang 110001, China
2Department of Anesthesiology, Central Hospital, Shenyang Medical College, Shenyang 110024, China

Correspondence should be addressed to Xiaojing Jiang

Received 21 March 2017; Revised 15 May 2017; Accepted 28 May 2017; Published 19 June 2017

Academic Editor: Shuang-En Chuang

Copyright © 2017 Jinghua Jiao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


With its high worldwide mortality and morbidity, cancer has gained increasing attention and novel anticancer drugs have become the focus for cancer research. Recently, studies have shown that most anesthetic agents can influence the activity of tumor cells. Midazolam is a γ-aminobutyric acid A () receptor agonist, used widely for preoperative sedation and as an adjuvant during neuraxial blockade. Some studies have indicated the potential for midazolam as a novel therapeutic cancer drug; however, the mechanism by which midazolam affects cancer cells needs to be clarified. This systematic review aims to summarize the progress in assessing the molecular mechanism of midazolam as an anticancer agent.